2017 Compounding Drug Development 
pharmaphorum
MARCH 24, 2022
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine.
European Pharmaceutical Review
OCTOBER 31, 2022
Solving this before the clinical stage ensures the viability of compounds…” Addressing bioavailability challenges in the first phases of development is essential to help create the most robust product profile and increase the potential for success as small molecule drugs move to the clinic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
DECEMBER 21, 2022
What sponsors should know about psychedelic drug development. Although some psychedelics have a long history in traditional medicine, regulatory agencies must evaluate psychedelic compounds the same way they assess any other drug. Psychedelic compounds are assessed by regulators the same way as any other drug.
RX Note
JULY 8, 2023
Introduction Drug development is an expensive and lengthy process , taking about 2-3 billion dollars and over 10 years to discover and develop a drug to commercialization. Drug Development Timeline Discovery and Development Research for a new drug begins in the laboratory.
pharmaphorum
MARCH 2, 2022
The term ‘psychedelic treatments’ incorporates a broad spectrum of different compounds, from LSD, psilocybin and DMT, to MDMA, ibogaine and ketamine. The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine), after being developed by Janssen.
European Pharmaceutical Review
JUNE 24, 2022
The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.
Pharmaceutical Technology
JANUARY 23, 2023
Mirikizumab has lost significant ground in the anti-IL23 drug class to AbbVie’s Skyrizi, and to a lesser extent Janssen’s Tremfya. In addition to Skyrizi’s recent supplementary CD indication, both Tremfya and Skyrizi received US FDA approval in psoriasis in 2017 and in 2019, respectively. Ther Innov Regul Sci.
Expert insights. Personalized for you.
105 
Let's personalize your content